NVCT - nuvectis.com Real Price to Acquire Entire Company

Brandmark of Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma, Inc. (NVCT) operates in a segment with colossal demand for effective cancer treatments, where the need for new therapies remains independent of economic downturns. The business faces intense pressure from global pharmaceutical behemoths and risks of clinical trial delays. This chart illustrating the company's valuation history is 584.05, while unique patents and strict FDA oversight provide asset protection.

Nuvectis Pharma - NVCT Enterprise Value (period 11/23/2025 - 10/30/2026)

Summary analytical data breakdowns for Nuvectis Pharma, Inc. (NVCT)

- stock price and consensus target price:
Price Chart Nuvectis Pharma Inc.|NVCT - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Nuvectis Pharma|NVCT - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Price of a Share Nuvectis Pharma|NVCT - Book Capitalization|Market Value to Equity Ratio nuvectis.com|NVCT - Company Total Assets
- company total debt and liquidity indicators:
Debt to Capital Nuvectis Pharma, Inc.|NVCT - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio nuvectis.com|NVCT - Company Aggregate Debts|Debts to Book Value Nuvectis Pharma|NVCT - Company Long-Term Debt|Company Short-Term Loans and Borrowings Nuvectis Pharma|Quick Ratio nuvectis.com
- financial results and valuation multiples details:
NVCT - Company Net Income
Summary company analytics:Nuvectis Pharma, Inc.
Manufactured product of Nuvectis Pharma Inc.

Enterprise Value is used for an objective asset valuation, combining market capitalization with net debt to determine the total cost of acquiring the business. By analyzing the market value while accounting for liquidity and liabilities at the level of 584.05, an investor sees the real financial weight of Nuvectis Pharma, Inc. (NVCT), which in biopharmaceuticals depends not on economic cycles, but on the volume of R&D capital and regulatory successes.

Competitors of Nuvectis Pharma, Inc. (NVCT)

Incyte Corp - Total Company Value|HUTCHMED Ltd - Enterprise Value|Nuvation Corp (NUVB) - Real Price to Acquire Entire Company|DAWN (Day One) - Real Price to Acquire Entire Company|MNPR: Aggregate Business Value|INBX (Inhibrx Biosciences, Inc.) - Enterprise Value|IMAB - Full Takeover Company Value|Enterprise Value FENC|HRTX - Total Enterprise Value|Total Company Value Coherus CHRS|CRBP: Business Value|Cardiff Oncology Corp - Enterprise Value|Total Enterprise Value BeyondSpring, Inc.|bioatla.com (BCAB) - Total Company Value|Lixte Biotechnology, Inc. - Value Adjusted for Debt and Cash|CTXR (Citius Pharmaceuticals Inc.) - Enterprise Value|Enterprise Value cellectar.com|Total Company Value BioLineRx (BLRX)|Total Company Value CANF (Can-Fite BioPharma Ltd)|Aprea Therapeutics, Inc. - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash KZIA|SLXN - Total Company Value|Total Enterprise Value NuCana plc|Chimerix (CMRX) - Total Company Value|Business Value CYCC|GTHX (G1 Therapeutics Inc.) - Enterprise Value|Real Price to Acquire Entire Company Kronos Bio Corporation (KRON)|Total Company Value Kintara Therapeutics (KTRA)|ONCT - Total Enterprise Value|Total Company Value Portage Biotech PRTG